A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 242 participants.
Also called NCT03226899
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 242 participants
- Sponsor
- Registry
-
NCT03226899
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Hungary, Poland
- Registry status
- Terminated
Technical summary
Registry record NCT03226899. Randomized; triple masking; primary purpose treatment. Start 2017-07-19 (actual); primary completion 2019-02-25 (actual). Results posted on 2021-11-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
- Condition
- Gout
- Intervention (Drug)
- Lesinurad
- Intervention (Drug)
- XOI
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- colchicine
- Intervention (Drug)
- corticosteroids
- Lead sponsor
- Ironwood Pharmaceuticals, Inc.
- Collaborator
- Medpace, Inc.
Record details
- Record id
cardio:ct-nct03226899- Content hash
fa750549ae307b7ef35207f978fcd97bb1fa2f59d824569a774ec723b48f576a